AMZN
Amazon.com, Inc.
AMZN has the edge over RGS overall, supported by lower modeled downside and stronger modeled upside.
RGS
Regis Corporation
RGS trails on the overall score without a compensating advantage in the available component scores.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
RGS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Stable | |
| Under pressure |
RGS's profitability and cash flow are currently stable, but its revenue and balance sheet are under pressure.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN has the edge over RGS in the historical PE scenario, which offers more potential upside but is not a forecast.
RGS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 0.5x | $1.05 | -96% |
| Fair | 0.6x | $1.27 | -95% |
| Expensive | 0.7x | $1.39 | -94% |
| Current | 11x | $23.55 | — |
Historical ranges are pointers, not guarantees.
RGS's PE is in its expensive range at 11x.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for AMZN, with profitability improving.
RGS Forward outlook
There aren't enough analyst estimates for RGS to show an outlook.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over RGS on earnings, with more consistent year-over-year improvement.
RGS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $2.10 | -96% |
| Q2 2026 | $2.41 | -95% |
| Q1 2026 | $44.58 | +9.4% |
| Q4 2025 | $44.40 | +12% |
| Q3 2025 | $46.95 | +26% |
| Q2 2025 | $46.10 | +20% |
| Q1 2025 | $40.74 | +$42.71 |
| Q4 2024 | $39.66 | +$41.43 |
RGS's earnings per share have fallen from their peak: $2.10 over the past year, against $46.95 in late 2025.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over RGS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over RGS on profitability, with a higher operating margin.
RGS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.3M | -7.8% |
| Q2 2026 | $56M | -7.3% |
| Q1 2026 | $52.4M | -8% |
| Q4 2025 | $57.1M | +22% |
| Q3 2025 | $59M | +28% |
| Q2 2025 | $60.4M | +22% |
| Q1 2025 | $57M | +16% |
| Q4 2024 | $46.7M | -8.5% |
RGS's revenue fell from its 2019 peak and has held roughly level since: $54M last quarter, down 7.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.8% | -0.3 points |
| Q2 2026 | 12% | -0.3 points |
| Q1 2026 | 11% | +2.1 points |
| Q4 2025 | 11% | -0.9 points |
| Q3 2025 | 10% | +5.4 points |
| Q2 2025 | 12% | +2.8 points |
| Q1 2025 | 8.8% | +0.5 points |
| Q4 2024 | 12% | +2.4 points |
RGS's operating margin was 9.8% last quarter, about level with the same quarter a year ago.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
RGS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.1M | +11% |
| Q2 2026 | $3.6M | -42% |
| Q1 2026 | $4.8M | -19% |
| Q4 2025 | $891K | -48% |
| Q3 2025 | $1.9M | +$3.2M |
| Q2 2025 | $6.2M | +23% |
| Q1 2025 | $5.9M | +$6.2M |
| Q4 2024 | $1.7M | +$5.9M |
RGS has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has the edge over RGS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
RGS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +44K shares |
| 1 year | +5.1% | +142K shares |
| 3 years | +24% | +561K shares |
| 5 years | +59% | +1.1M shares |
| Available history | +63% | +1.1M shares |
RGS has 3M diluted shares, up 5.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | $1,000 |
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN has the edge over RGS on leverage, with a lower net debt burden relative to earnings.
RGS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.2x | Elevated |
| Q2 2026 | 3.2x | Elevated |
| Q1 2026 | 3.2x | Elevated |
| Q4 2025 | 3.4x | Elevated |
| Q3 2025 | 3.5x | Elevated |
| Q2 2025 | 4.1x | High |
| Q1 2025 | 4.8x | High |
| Q4 2024 | 5.2x | High |
RGS's net debt is about 3.2 years of its operating earnings (EBITDA), down from 3.5 years a year ago.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
RGS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.3 | Neutral |
| Stochastic | 35.1 | Neutral |
RGS's weekly RSI is 36 (neutral) and its Stochastic is 35 (neutral).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
RGS PE vs Consumer Cyclical Sector
| Metric | RGS | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 18x | 38% below |
| PE % | 92 | 47 | 45 pts above |
RGS has the edge over AMZN on valuation relative to its sector.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over RGS on trend strength, trading above more of its moving averages.
RGS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.8 | 15% below |
| 20 week MA | $27.7 | 15% below |
| 50 week MA | $26.5 | 11% below |
| 100 week MA | $24.8 | 5% below |
| 200 week MA | $21.2 | 11% above |
RGS has fallen below most of its moving averages, though it's still 11% above its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over RGS on returns for 2026, with the stronger performance.
RGS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $359.0 | $189.6 | -47% |
| 2021 | $189.6 | $33.8 | -82% |
| 2022 | $33.8 | $24.2 | -28% |
| 2023 | $24.2 | $9.45 | -61% |
| 2024 | $9.45 | $25.5 | +170% |
| 2025 | $25.5 | $27.4 | +7.4% |
| 2026 YTD | $27.4 | $23.6 | -14% |
RGS's yearly returns have swung widely, from +170% in 2024 to −82% in 2021. It's down 14% so far in 2026.